|
 |
| home > pmps > autumn 2002 > high noon for a global player in parenteral drug delivery systems and medical diagnostics |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Since its incorporation in the early 1960s, Meridian Medical Technologies has positioned itself on probably the most important frontier, ready to advance into sterile manufacturing. Dr Patricia Lobo, Editor of PMPS speaks to J. Donald Ferry, General Manager Manufacturing and Thomas Handel, Vice President of Sales at Meridian
Could you briefly describe what your company is involved in?
Meridian Medical Technologies (MMT) is the successor company which resulted from a merger between Brunswick Biomedical (cardiopulmonary devices) and Survival Technology (parenteral drug delivery) in 1996. Survival Technology was incorporated in the early 1960s. Today, Meridian has two operating divisions, Cardiopulmonary Systems and Specialty Pharmaceuticals.
The cardiopulmonary products range from portable monitors that transmit biometrics information (blood oxygen, heat rate and electrical activity, pulmonary performance) to hospital-based technology. Our hospital-based technology is called the PRIME ECG (cardiac mapping system). This technology utilises an 80-lead, vest-like sensor which produces a 3-dimensional map of the heart, providing a more accurate means of diagnosing heart attacks over the standard 12-lead ECG.
The Specialty Pharmaceuticals business specialises in a drug delivery technology called the autoinjector. These devices allow the patient to automatically deliver a measured dosage of product. These have been used to administer products such as antidotes, products for pain management, migraine, cardiac events (LidoPen®) and severe allergic reactions (EpiPen®).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
